A Phase 2, Randomized, Double-blind Study to Evaluate the Efficacy and Safety of VX-561 in Subjects Aged 18 Years and Older With Cystic Fibrosis
Latest Information Update: 27 Jan 2022
At a glance
- Drugs Deutivacaftor (Primary) ; Ivacaftor
- Indications Cystic fibrosis
- Focus Therapeutic Use
- Sponsors Vertex Pharmaceuticals
Most Recent Events
- 09 Oct 2020 This trial has been completed in Belgium according to European Clinical Trials Database record.
- 17 Sep 2020 Status changed from active, no longer recruiting to completed.
- 20 Jun 2020 This trial has been completed in Germany according to European Clinical Trials Database record.